HANWHA, A KIIC MEMBER, INVESTED & PARTNERED WITH INFINIDOME, THE TOP ISRAELI SOLUTION FOR GNSS PROTECTION
Hanwha, A Prominent Korean Defense Conglomerate, Invested In Israeli Company Infinidome, A Developer Of Advanced Anti-jamming Protection For Gnss (Satellite Navigation Systems)
InfiniDome's patented technology, experienced team, and defense market focus impressed Hanwha, who recognized their strong partnerships with companies like Honeywell, US Army & DoD, IDF (Israel Defense Forces), IAI (Israel Aerospace Industries), Elbit, Easy Aerial
The agreement includes:
-
Strategic investment
-
Implementation Partnership
-
Joint R&D
-
Potential exclusivity in future commercial agreements
The deal was finalized after extensive visits to Israel, encompassing due diligence, demonstrations, tours, legal scrutiny, and term sheet signing.
A KIIC MEMBER, INVESTED & PARTNERED WITH ASSEMBRIX, A LEADING ISRAELI SOLUTION FOR ADDITIVE MANUFACTURING TECHNOLOGY
KIIC's member identified AM and 3D printing as a focus area and was seeking innovation and investment opportunities
Assembrix, a standout solution in SaaS IP-protected control platforms for 3D printing, was identified among 14 screened options:
-
Strong business fit
-
Skilled team
-
Outstanding client partnerships such as giant aerospace company- Boeing
KIIC streamlined the process, handling research, screening, and delegation planning.
By investing and partnering with Assembrix - KIIC Member extended the reach of a renowned Korean steel manufacturer, presenting innovations beyond traditional materials and conventional steel.
A PROMINENT KOREAN CONSTRUCTION & FARM EQUIPMENT COMPANY PARTNERED WITH OTONOMO, A LEADING PROVIDER OF AUTOMOTIVE CONNECTIVITY AND DIGITALIZATION SOLUTIONS
KIIC's member sought to enter the automotive connectivity and digitalization space to:
-
Utilize their data effectively
-
Create new services
-
Generate additional revenue
-
Improve efficiency
KIIC's extensive research and scouting resulted in a collaboration with Otonomo, a leading cloud-based solution:
-
Otonomo ensures data privacy through cleansing, normalization, and anonymization, providing valuable insights.
-
Otonomo has gained support from notable venture capital firms and strategic investors such as:
SK Group, NTT DOCOMO, Aptiv, Bessemer Ventures, Dell Technologies, Maniv Mobility (Israel leader in automotive), StageOne and more -
Established partnerships with global entities like Daimler, BMW, Ford, Renault/Citroen, among others
A KIIC MEMBER INVESTED IN IMMPACT BIO, DEVELOPER OF AN ONCOLOGY CAR-T-BASED THERAPEUTICS SOLUTION
KIIC member has identified CAR-T Immunotherapy as a focus area, aiming to expand oncology novel solutions and therapeutics portfolio.
KIIC's extensive research and scouting resulted in a strategic investment in ImmPACT Bio, a clinical-stage biopharmaceutical Israeli company:
-
Developing a novel strategy for improving current CAR-T therapies while simultaneously offering a solution for treating solid cancers
-
An executive team that brings clinical and commercial experience from leading companies such as Kite Pharma and Amgen
-
Backed by prominent Israeli Biotech incubator FutuRX and notable investors including OrbiMed, J&J, Takeda, Novartis, and Israel Innovation Authority
The investment was made alongside Tier 1 global VCs, enhancing the network and investor relations of the KIIC member for future co-investment opportunities.
Despite the challenges posed by Covid-19, the entire process, including scouting, introduction, startup due diligence, and legal framework establishment, was successfully conducted remotely.
A KIIC MEMBER INVESTED IN CHMOMAB, DEVELOPER OF ANTIBODIES FOR IMMUNE-MEDIATED AND FIBROTIC DISORDERS SOLUTION
KIIC member has identified Antibodies Therapeutic solutions, aiming to diversify its portfolio with solutions and therapeutics for immune-mediated and fibrotic disorders, including orphan diseases.
KIIC's extensive research and scouting resulted in a strategic investment in ChemomAB, a developer of Monoclonal Antibodies for Immune-mediated and Fibrotic Disorders Solutions:
-
Strong business fit
-
Strong team, bringing experience from top companies such as Pharmos, Teva cCAM, and more
-
Impressive investor list: OrbiMed and Serial entrepreneur Mr. Peter Thiel
The investment was made alongside Tier 1 global VCs, enhancing the network and investor relations of the KIIC member for future co-investment opportunities.
6 months after placing the investment-
ChemomAB was merged with Anchiano Therapeutics
-
Current shareholders of Chemomab will own ~90% of the combined company upon closing
-
Anchiano Therapeutics skies 182.5% after signing the merger agreement
